Discovery of Phenylaminopyridine Derivatives as Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
暂无分享,去创建一个
Doohyun Lee | Sung-Jun Han | Wonyoung So | Peter Sommer | Suyeon Jo | Inhee Choi | J. Cechetto | Sung-jun Han | Inhee Choi | Junwon Kim | Yoonae Ko | M. Liuzzi | Jiyoun Nam | Junghwan Kim | Z. No | Jinhwa Lee | Michel Liuzzi | Junwon Kim | Changmin Park | Taedong Ok | W. So | Mina Jo | Youngmi Kim | Youngsam Park | M. Ju | Tae-Hee Kim | P. Sommer | Changmin Park | Mina Jo | Taedong Ok | Jeongjin Kwon | Sunju Kong | Youngmi Kim | Jihyun Choi | Hyoung Cheul Kim | Yoonae Ko | Youngsam Park | Jaewan Yoon | Moon Kyeong Ju | Junghwan Kim | Tae-Hee Kim | Jonathan Cechetto | Jiyoun Nam | Jinhwa Lee | Zaesung No | Sunju Kong | Doohyun Lee | Jihyun Choi | Suyeon Jo | Jeongjin Kwon | Jaewan Yoon | Hyoung Cheul Kim | Jonathan Cechetto
[1] Peng Zhan,et al. Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms. , 2012, Journal of medicinal chemistry.
[2] Brian A. Chauder,et al. Novel 4,4-disubstituted piperidine-based C-C chemokine receptor-5 inhibitors with high potency against human immunodeficiency virus-1 and an improved human ether-a-go-go related gene (hERG) profile. , 2011, Journal of medicinal chemistry.
[3] N. Apostolova,et al. Twenty years of HIV-1 non-nucleoside reverse transcriptase inhibitors: time to reevaluate their toxicity. , 2011, Current Medicinal Chemistry.
[4] E. De Clercq,et al. Recent advances in DAPYs and related analogues as HIV-1 NNRTIs. , 2011, Current medicinal chemistry.
[5] F. Fleming,et al. Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore. , 2010, Journal of medicinal chemistry.
[6] Xiaohong Liu,et al. Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. , 2010, Journal of medicinal chemistry.
[7] E. Clercq. Highlights in the discovery of antiviral drugs: a personal retrospective. , 2010 .
[8] Youcef Mehellou,et al. Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? , 2010, Journal of medicinal chemistry.
[9] Marie-Pierre de Béthune,et al. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). , 2010, Antiviral research.
[10] R. Paredes,et al. Clinical management of HIV-1 resistance. , 2010, Antiviral research.
[11] T. Hawkins. Understanding and managing the adverse effects of antiretroviral therapy. , 2010, Antiviral research.
[12] S. Khoo,et al. Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. , 2010, Antiviral research.
[13] M. Lv,et al. Developments of indoles as anti-HIV-1 inhibitors. , 2009, Current pharmaceutical design.
[14] S. Kiertiburanakul,et al. Emerging of HIV drug resistance: epidemiology, diagnosis, treatment and prevention. , 2009, Current HIV research.
[15] G. McGaughey,et al. Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses. , 2008, Journal of medicinal chemistry.
[16] M. Falagas,et al. Mortality and morbidity of HIV infected patients receiving HAART: a cohort study. , 2008, Current HIV research.
[17] S. Natarajan,et al. 1,3‐Diketones from Acid Chlorides and Ketones: A Rapid and General One‐Pot Synthesis of Pyrazoles. , 2006 .
[18] T. Maurer,et al. Use of Immortalized Human Hepatocytes to Predict the Magnitude of Clinical Drug-Drug Interactions Caused by CYP3A4 Induction , 2006, Drug Metabolism and Disposition.
[19] Z. Rankovic,et al. Medicinal chemistry of hERG optimizations: Highlights and hang-ups. , 2006, Journal of medicinal chemistry.
[20] H. M. Vinkers,et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. , 2004, Journal of medicinal chemistry.
[21] J. Sahi,et al. Induction of Drug Metabolism Enzymes and MDR1 Using a Novel Human Hepatocyte Cell Line , 2004, Journal of Pharmacology and Experimental Therapeutics.
[22] A. Mocroft,et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study , 2003, The Lancet.